Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
1.250
-0.080 (-6.02%)
At close: Feb 21, 2025, 4:00 PM
1.220
-0.030 (-2.40%)
After-hours: Feb 21, 2025, 7:53 PM EST
Kairos Pharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
3
Market Cap
16.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKAPA News
- 4 days ago - Kairos Pharma Announces New Department of Defense Funding for Research of ENV205 - Business Wire
- 11 days ago - Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial - Business Wire
- 16 days ago - Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma - Business Wire
- 25 days ago - Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024 - Business Wire
- 4 weeks ago - Kairos Pharma Provides Business Update and Outlook into 2025 - Business Wire
- 6 weeks ago - Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit - Business Wire
- 2 months ago - Kairos Pharma: Potential To Remove Resistance With Established Drugs - Seeking Alpha
- 2 months ago - Kairos Pharma to Participate in The Microcap Conference in January 2025 - Accesswire